Clinical trials: Recurrent Female Reproductive System Carcinoma
Recurrent Ovarian Cancer, Platinum-sensitive Ovarian Cancer
Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer
This is a prospective, open-label, single-arm, multicenter exploratory clinical study designed to evaluate the efficacy and safety of iparomlimab/tuvonralimab (QL1706), a bispecific antibody targeting programmed cell death…
- Trial name
- NCT07454018
- Testing
- Iparomlimab/Tuvonralimab
- Volunteers
- 45 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Ovarian Cancer
Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer
RATIONALE: Estrogen can cause the growth of ovarian epithelial cancer cells. Hormone therapy using fulvestrant may fight ovarian cancer by blocking the use of estrogen by the tumor cells.
- Trial name
- NCT00617188
- Testing
- Fulvestrant
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Masonic Cancer Center, University of Minnesota